These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17665327)

  • 61. Analysis of the pathogenicity locus in Clostridium difficile strains.
    Cohen SH; Tang YJ; Silva J
    J Infect Dis; 2000 Feb; 181(2):659-63. PubMed ID: 10669352
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Review: Clostridium difficile-associated disorders/diarrhea and Clostridium difficile colitis: the emergence of a more virulent era.
    Hookman P; Barkin JS
    Dig Dis Sci; 2007 Apr; 52(4):1071-5. PubMed ID: 17380404
    [No Abstract]   [Full Text] [Related]  

  • 63. [Infections caused by Clostridium difficile].
    Rodríguez-Pardo D; Mirelis B; Navarro F
    Enferm Infecc Microbiol Clin; 2013 Apr; 31(4):254-63. PubMed ID: 23411363
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clostridium difficile--associated diarrhea.
    Johnson S; Gerding DN
    Clin Infect Dis; 1998 May; 26(5):1027-34; quiz 1035-6. PubMed ID: 9597221
    [No Abstract]   [Full Text] [Related]  

  • 65. Carbohydrate recognition by Clostridium difficile toxin A.
    Greco A; Ho JG; Lin SJ; Palcic MM; Rupnik M; Ng KK
    Nat Struct Mol Biol; 2006 May; 13(5):460-1. PubMed ID: 16622409
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Oncologic aspects of Clostridium difficile].
    Telekes A
    Orv Hetil; 2016 Jul; 157(28):1110-6. PubMed ID: 27397423
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Six years evaluation of Clostridium difficile associated diarrhea].
    Ercis S; Ergin A; Hasçelik G
    Mikrobiyol Bul; 2004; 38(1-2):45-50. PubMed ID: 15293901
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibiotic profiling of Clostridium difficile ribotype 176--A multidrug resistant relative to C. difficile ribotype 027.
    Krutova M; Matejkova J; Tkadlec J; Nyc O
    Anaerobe; 2015 Dec; 36():88-90. PubMed ID: 26256807
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Infectious disease threats: what are we to do? Preface.
    Paauw DS
    Med Clin North Am; 2013 Jul; 97(4):xiii-xiv. PubMed ID: 23809724
    [No Abstract]   [Full Text] [Related]  

  • 70. New trends in Clostridium difficile virulence and pathogenesis.
    Denève C; Janoir C; Poilane I; Fantinato C; Collignon A
    Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S24-8. PubMed ID: 19303565
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nonantimicrobial drug targets for Clostridium difficile infections.
    Darkoh C; Deaton M; DuPont HL
    Future Microbiol; 2017 Sep; 12(11):975-985. PubMed ID: 28759258
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Susceptibility of Clostridium difficile toward antimicrobial agents used as feed additives for food animals.
    Aarestrup FM; Tvede M
    Microb Drug Resist; 2011 Mar; 17(1):125-7. PubMed ID: 20950192
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice.
    Kaur S; Vaishnavi C; Prasad KK; Ray P; Kochhar R
    Microbiol Immunol; 2007; 51(12):1209-14. PubMed ID: 18094539
    [TBL] [Abstract][Full Text] [Related]  

  • 74. First report of Clostridium difficile NAP1/027 in a Mexican hospital.
    Camacho-Ortiz A; López-Barrera D; Hernández-García R; Galván-De Los Santos AM; Flores-Treviño SM; Llaca-Díaz JM; Maldonado-Garza HJ; Bosques-Padilla FJ; Garza-González E
    PLoS One; 2015; 10(4):e0122627. PubMed ID: 25915544
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evidence for low risk of Clostridium difficile infection associated with tigecycline.
    Wilcox MH
    Clin Microbiol Infect; 2007 Oct; 13(10):949-52. PubMed ID: 17697004
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [A new virulent clone of Clostridium difficile is a challenge for Danish hospitals].
    Schønheyder HC; Kristensen B
    Ugeskr Laeger; 2009 May; 171(19):1578. PubMed ID: 19419636
    [No Abstract]   [Full Text] [Related]  

  • 77. The changing face of Clostridium difficile: what treatment options remain?
    Shen EP; Surawicz CM
    Am J Gastroenterol; 2007 Dec; 102(12):2789-92. PubMed ID: 18042108
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pathogenesis of Clostridium difficile infection.
    Borriello SP
    J Antimicrob Chemother; 1998 May; 41 Suppl C():13-9. PubMed ID: 9630370
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Probiotics for recurrent Clostridium difficile disease.
    Lawrence SJ; Korzenik JR; Mundy LM
    J Med Microbiol; 2005 Sep; 54(Pt 9):905-906. PubMed ID: 16091446
    [No Abstract]   [Full Text] [Related]  

  • 80. Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and Streptococcus mutans glucosyltransferases.
    von Eichel-Streiber C; Sauerborn M; Kuramitsu HK
    J Bacteriol; 1992 Oct; 174(20):6707-10. PubMed ID: 1307487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.